<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604563</url>
  </required_header>
  <id_info>
    <org_study_id>201511019</org_study_id>
    <nct_id>NCT02604563</nct_id>
  </id_info>
  <brief_title>Aging, Geriatric Syndromes and Clonal Hematopoiesis</brief_title>
  <official_title>Aging, Geriatric Syndromes and Clonal Hematopoiesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edward P. Evans Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will incorporate a wide range of clinical variables
      associated with aging and cardiovascular disease to determine whether they are associated
      with mutation status independent of chronologic age. Clinically, aging can be operationalized
      using geriatric assessment, which entails a comprehensive multi-dimensional assessment of the
      health of an older adult, including measures of comorbidity, polypharmacy, functional status,
      cognition, depression, falls, social activities and social support. Given that aging is
      heterogeneous, geriatric assessment allows greater specificity for aging than chronological
      age alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Background mutation rate in hematopoietic stem cells from older adults regardless of a prior cancer diagnosis as measured by the number and frequency of hematopoietic-specific mutations</measure>
    <time_frame>Estimated to be 10 years</time_frame>
    <description>-The investigators will sequence the coding region of some or all of the genes in an individual's blood cells and compare results to their matched mouth cells to define hematopoietic-specific mutations. The number of hematopoietic-specific mutations per individual and the frequency of individuals with mutations will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence or absence of geriatric syndromes as measured by hematopoietic stem cell mutations</measure>
    <time_frame>Estimated to be 10 years</time_frame>
    <description>-The presence or absence of geriatric syndromes will be correlated with the mutation status of individuals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the natural history of mutations in older adults with clonal hematopoiesis as measured by risk to develop blood cancer/geriatric syndrome/illness/cardiovascular disease</measure>
    <time_frame>Estimated to be 10 years</time_frame>
    <description>-Individuals with mutations will be followed longitudinally to monitor the fraction of hematopoietic cells with mutations, the functional consequences of mutations in their blood cells, and the risk of developing a blood cancer, geriatric syndrome, cardiovascular disease, or other illness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence or absence of cardiovascular disease as measured by hematopoietic stem call mutations</measure>
    <time_frame>Estimated to be 10 years</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Geriatrics</condition>
  <condition>Aged</condition>
  <condition>Geriatric Syndromes</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <description>Complete several self-administered health assessments at baseline and every 6 months until death.
Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.
Peripheral blood draw will occur at baseline and no more than every 6 months until death.
Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death
May be approached about optional bone marrow biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <description>Complete several self-administered health assessments at baseline and every 6 months until death.
Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.
Peripheral blood draw will occur at baseline and no more than every 6 months until death.
Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death
May be approached about optional bone marrow biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
    <description>Complete several self-administered health assessments at baseline with no further follow-up
Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline with no further follow-up
Peripheral blood draw will occur at baseline with no further follow-up
Buccal swabs will occur at baseline with no further follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Hip replacement</arm_group_label>
    <description>Complete several self-administered health assessments at baseline and every 6 months until death.
Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.
Participants with or without clonal hematopoiesis who are undergoing hip replacement
Peripheral blood draw will occur at baseline and no more than every 6 months until death.
Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death
May be approached about optional bone marrow biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Assessment</intervention_name>
    <description>-Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Activities of Daily Living Questionnaire</intervention_name>
    <description>10 items about daily functional status
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Instrumental Activities of Daily Living, subscale of the OARS</intervention_name>
    <description>7 items about daily functional status
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Karnofsky Self-reported Performance Rating Scale</intervention_name>
    <description>1 item about daily functional status
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Number of Falls</intervention_name>
    <description>1 item about daily functional status
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical Health Section, subscale of the OARS</intervention_name>
    <description>13 items about comorbidity
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MOS Social Activity Survey</intervention_name>
    <description>4 items about social activity
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Unintentional Weight Loss</intervention_name>
    <description>2 items about nutrition
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Peripheral Blood Draw</intervention_name>
    <description>-Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Buccal Swab</intervention_name>
    <description>Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heart Health and Smoking History from BRFSS questionnaire</intervention_name>
    <description>7 items about heart health and smoking history
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gait Speed</intervention_name>
    <description>Research coordinator will test gait speed
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Grip Strength</intervention_name>
    <description>Research coordinator will test grip strength
Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Height and Weight measurements</intervention_name>
    <description>-Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood pressure measurement</intervention_name>
    <description>-Baseline and no more frequently than every 6 months until death</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm C: No clonal hematopoiesis &amp; no follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Optional bone marrow biopsy</intervention_name>
    <description>-1 optional bone marrow biopsy</description>
    <arm_group_label>Arm A: Clonal hematopoiesis</arm_group_label>
    <arm_group_label>Arm B: No clonal hematopoiesis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Peripheral blood

        -  Buccal swab or tongue brushing

        -  Optional bone marrow biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants seen in Washington University School of Medicine clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 50 years of age.

          -  Able to understand written and spoken English.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document.

        Exclusion Criteria:

          -  Inability or unwillingness to complete health questionnaire.

          -  History of a recent (&lt;30 days) acute viral illness.

          -  Current cancer diagnosis and currently receiving chemotherapy or undergoing radiation
             therapy. A prior history of cancer is allowed if the participant completed therapy &gt; 1
             year prior to enrollment; participants with a prior diagnosis of cancer will be asked
             to sign a release of information for the research team to obtain records regarding
             their prior cancer treatment.

          -  Current use of drugs that cause DNA damage (e.g. Cytoxan, azathioprine, etc.) for the
             treatment of a non-malignant disease.

          -  Vulnerable populations (e.g. prisoners).

          -  Known infection with Hepatitis B or C, HTLV, or HIV.

          -  Additional exclusion for optional bone marrow aspirate/biopsy substudy:

               -  Use of medications for anticoagulation or &quot;blood thinning&quot; including warfarin,
                  low molecular weight heparins (enoxaparin, daltaparin) or direct-acting oral
                  anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban or betrixaban)

               -  allergy to lidocaine or other local anesthetics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Wildes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanya Wildes, M.D.</last_name>
    <phone>314-362-5817</phone>
    <email>twildes@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristina Williams, B.S.</last_name>
    <phone>314-362-6963</phone>
    <email>kjw1@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Wildes, M.D.</last_name>
      <phone>314-362-5817</phone>
      <email>twildes@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristi Williams, B.S.</last_name>
      <phone>314-362-6963</phone>
      <email>kjw1@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tanya Wildes, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Ley, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Walter, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Duncavage, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

